CRISPR Cas9 Market

Market Definition:

The CRISPR Cas9 Market size was valued at USD 2.94 billion in 2022, and is predicted to reach USD 12.22 billion by 2030, with a CAGR of 19.52% from 2023 to 2030. CRISPR Cas9 is an enzyme and genome-editing tool used by researchers to modify gene function and alter DNA sequences.

Also, it was adapted from a naturally-occurring genome editing system in bacteria and these bacteria are used to create DNA segments known as CRISPR arrays. Moreover, it is used to treat inherent disorders, such as thalassemia and hemophilia, and diseases arising from somatic mutations such as cancer and AIDS. Furthermore, they are used in the creation of genetically modified organisms, new medicines, and agricultural products.

Market Dynamics and Trends

The demand for CRISPR Cas9 is increasing due to the rise in concern for deaths from various diseases such as cancer, stroke, and Alzheimer. Also, factors such as the risk of congenital abnormalities, rise in requirement in drug research, and late pregnancies resulting in birth problems are expected to propel the growth of the market during the forecast period. Moreover, the upgradation to the newer versions of the protein such as SpCas9-HF and eSpCas9 to lower the off-target editing activity drives the market growth.

However, the usage of this technology has led to ethical concerns, owing to the factors such as lack of consent for germline therapy and the possibility of off-target effects. This factor is expected to restrain the growth of the market during the forecast period. On the other hand, the emergence of advanced applications such as the use of DNA-free Cas9 in rice lettuce, grapevine, apple protoplasts, and tobacco is expected to create lucrative opportunities for the CRISPR Cas9 market in the future. 

Market Segmentations and Scope of the Study

The CRISPR Cas9 market is segmented based on product, service, application, end user, and geography. Based on the product, the market is classified into kits & enzymes, vector-based Cas, DNA-Free Cas, antibodies, libraries, design tool, and others. Based on service, the market is categorized into cell line engineering, gRNA design, microbial gene editing, and DNA synthesis. Based on the application, the market is classified into biomedical, genome engineering, disease model studies, functional genomics, epigenetics, agricultural, and others. Based on end user, the market is classified into biotechnology & pharmaceutical companies, academics & government research institutes, and contract research organizations (CROs). The geography breakdown and analysis of each of the aforesaid segments includes regions such as North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis

North America holds the lion’s share of the global CRISPR Cas9 market, and is expected to continue to dominate the market during the forecast period. This is attributed to factors such as increasing funding in biotechnology and genomics programs and established healthcare infrastructure. Moreover, rise in the number of research partnerships drives the market growth in this region. In February 2020, Biogen, Inc. and Sangamo Therapeutics, Inc. announced their partnership agreement to commercialize and develop ST-501, ST-502, and undisclosed neuromuscular disease target.

However, Asia-Pacific is expected to show a steady rise in the CRISPR Cas9 market. CRISPR Cas9 is highly utilized in China for deleting genes in the livestock that inhibit muscle and hair growth. Also, the increase in biopharmaceutical R&D activities and the rise in the number of ongoing clinical trials are expected to drive the growth of the market during the forecast period in this region.

Competitive Landscape

The market comprises of various players such as OriGene Technologies, Inc., Horizon Discovery Ltd., Thermo Fisher Scientific, Takara Bio, Inc., Intellia Therapeutics, Inc., Merck KGaA, Editas Medicine, Caribou Biosciences, Inc., Crispr Therapeutics, and Mirus Bio LLC. These manufacturers are actively indulging in R&D initiatives, product & technology innovations, and industrial collaborations to enhance their product portfolio and geographical reach.

For instance, in March 2021, Caribou Biosciences, Inc., announced that it raised USD 115 million in Series C financing round. This funding will help the company advance Allogeneic Cell Therapy Pipeline and next-generation CRISPR technologies. Also, in December 2020, Intellia Therapeutics, Inc. announced its new preclinical data in support of NTLA-5001, Tumor 1 (WT1), and (TCR)-T cell therapy for the treatment of acute myeloid leukemia.

Key Benefits

• The CRISPR Cas9 market report provides the quantitative analysis of the current market and estimations from 2023 to 2030. This analysis assists in identifying the prevailing market opportunities to capitalize on.

• The study comprises of a detailed analysis of the CRISPR Cas9 market trends, including the current and future trends for depicting the prevalent investment pockets in the market.

• The information related to key drivers, restraints, and opportunities and their impact on the CRISPR Cas9 market is provided in the report. 

• The competitive analysis of the market players along with their market share in the CRISPR Cas9 market is mentioned.

• The SWOT analysis and Porter’s Five Forces model are elaborated in the study.

• The value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

Key Market Segments

By Product

• Kits & Enzymes

• Vector-Based Cas

• DNA-Free Cas

• Antibodies

• Libraries

• Design Tool

• Others

By Services

• Cell Line Engineering

• GRNA Design

• Microbial Gene Editing

• DNA Synthesis 

By Application

• Biomedical

• Genome Engineering

• Disease Model Studies

• Functional Genomics

• Epigenetics

• Agricultural

• Others

By End User

• Biotechnology & Pharmaceutical Companies

• Academics & Government Research Institutes

• Contract Research Organizations (CROs)

By Geography

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Italy

  • Germany

  • Spain

  • Netherlands

  • Rest of Europe

• Asia-Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Taiwan

  • Vietnam

  • Rest of Asia Pacific

• RoW

  • Latin America

  • Middle East 

  • Africa

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Analysis Period	2022–2030
Base Year Considered	2022
Forecast Period	2023–2030
Market Size Estimation	Billion (USD)
Market Segmentation	By Product (kits & enzymes, vector-based Cas, DNA-Free Cas, antibodies, libraries, design tool, and others) By Service (cell line engineering, gRNA design, microbial gene editing, and DNA synthesis) By Application (biomedical, genome engineering, disease model studies, functional genomics, epigenetics, agricultural, and others) By End- User (biotechnology & pharmaceutical companies, academics & government research institutes, and contract research organizations (CROs)
Geographical Segmentation	North America (U.S., Canada, Mexico) Europe (UK, Italy, Germany, Spain, Netherlands, Rest of Europe) Asia-Pacific (China, Japan, India, Australia, South Korea, Taiwan, Vietnam, Rest of Asia Pacific) RoW (Latin America, Middle East, Africa)
Companies Profiled	OriGene Technologies, Inc., Horizon Discovery Ltd., Thermo Fisher Scientific, Takara Bio, Inc., Intellia Therapeutics, Inc., Merck KGaA, Editas Medicine, Caribou Biosciences, Inc., Crispr Therapeutics, and Mirus Bio LLC

KEY PLAYERS

• OriGene Technologies, Inc.

• Horizon Discovery Ltd.

• Thermo Fisher Scientific

• Takara Bio, Inc.

• Intellia Therapeutics, Inc.

• Merck KGaA

• Editas Medicine

• Caribou Biosciences, Inc.

• Crispr Therapeutics

• Mirus Bio LLC